Crystalline solid and amorphous forms of (−)-halofenate and methods related thereto
The present invention provides crystalline solid and amorphous forms of (−)-halofenate. The crystalline solid forms may be used in various pharmaceutical compositions, and are particularly effective for the prevention and/or treatment of conditions associated with blood lipid deposition in a mammal, particularly those diseases related to Type 2 diabetes and hyperlipidemia. The invention also relates to a method for preventing or treating Type 2 diabetes and hyperlipidemia in a mammal comprising the step of administering a therapeutically effective amount of crystalline solid and amorphous forms of (−)-halofenate.
1. A compound of (−) halofenate in a crystalline solid form A characterized by an X-ray powder diffraction pattern comprising a peak at about 10.8°2θ, an infrared spectrum comprising at least one peak selected from about 3322 cm −1 and about 2886 cm −1 , and further characterized by at least one of:
no weight gain at a relative humidity of about 65%; and
a weight gain of about 1.6% at a relative humidity of about 95%.
2. The compound of claim 1 wherein the crystalline solid form A consists of greater than 95% (−)-halofenate and less than 5% of other non-solvent compounds.
3. A compound (−)-halofenate in a crystalline solid form A characterized by an X-ray powder diffraction pattern comprising peaks at about 10.8°2Θ, about 22.0°2Θ, and 29.3°2Θ, further characterized by at least one of:
an infrared spectrum comprising peaks at about 3322 cm −1 and about 2886 cm −1 , and
a Raman spectrum comprising peaks at about 3087 cm −1 and about 1663 cm −1 ,
and wherein the crystalline solid form A consists of greater than 95% (−)-halofenate and less than 5% of other non-solvent compounds.
4. A compound of (−) halofenate in a crystalline solid form A characterized by an X-ray powder diffraction pattern comprising a peak at about 10.8°2θ, an infrared spectrum comprising at least one peak selected from about 3322 cm −1 and about 2886 cm −1 wherein the crystalline solid form A consists of greater than 95% (−)-halofenate and less than 5% of other non-solvent compounds.